Olfen 75 (Diclofenac Sodium, Lidocaine Hydrochloride)

Diclofenac sodium, the active ingredient in Olfen 75, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as a 75 mg tablet for oral use. It reduces inflammation and pain in musculoskeletal conditions and is often combined with a local anesthetic for enhanced comfort.

GNH USA supplies Olfen 75 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olfen 75 combines diclofenac sodium with lidocaine to target inflammatory pain pathways. It is indicated for: - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: alleviates joint inflammation and stiffness. - Acute musculoskeletal sprain or strain: provides rapid pain relief and facilitates early movement.

Olfen 75 may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache or dizziness. - Mild skin rash or itching. - Localized burning at the site of lidocaine action.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic dysfunction indicated by elevated enzymes. - Renal impairment or sudden loss of kidney function.

When prescribing Olfen 75, consider the following safety measures: - Assess renal function: patients with impaired kidneys may require dose adjustment. - Monitor hepatic enzymes: liver disease can increase risk of toxicity. - Evaluate cardiovascular risk: NSAIDs may elevate blood pressure or precipitate events. - Avoid use in late pregnancy: risk of fetal ductus arteriosus closure. - Contraindications: known hypersensitivity to diclofenac, lidocaine or other NSAIDs. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olfen 75 can interact with several drug classes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): heightened gastrointestinal bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive renal and gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal perfusion. - Diuretics: potential for enhanced kidney function decline. - Lithium: NSAIDs can raise serum lithium levels. - Methotrexate: reduced clearance may increase toxicity.